Clinical Trial

Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to compare the efficacy and safety of two antibiotic combinations (Colistin + Meropenem) vs (Imipenem/cilastatin+ Tigecycline) in the treatment of adults with MDR gram-negative infections.
Trial Details
NCT Number NCT07524920
Lead Sponsor Ain Shams University
Conditions MDR Bacteria
Enrollment 60 participants
Start Date 2026-04-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-13